Lehigh Valley Health Network announced HNL Lab Medicine President and Chief Executive Officer Matthew R. Sorrentino will retire from the position this fall and be succeeded by current HNL Lab Medicine Board of Directors Chair and LVHN Board of Trustees Vice Chair Martin K. Till.

Sorrentino’s retirement is effective Oct. 15. Till will start in the new post on Sept. 1, to ensure a smooth leadership transition.

“HNL Lab Medicine has prospered under Matt’s leadership and commitment to excellence to become the preeminent lab medicine company in the region,” said Brian A. Nester, DO, MBA, president and Chief Executive Officer, LVHN. Sorrentino was directly involved in the founding of HNL and served for more than 20 years as HNL’s board secretary. “We are grateful for his hard work and service to HNL and the community,” Nester said.

Sorrentino assumed the top job at HNL Lab Medicine in May 2019, but his work with HNL and LVHN started decades earlier. He served as outside counsel for both organizations for almost 25 years and served as LVHN’s senior vice president and chief legal officer in recent years.

“Matt has devoted himself to first-class health care and lab services in this region, and we’re all better off because of his contributions,” Nester said. “The growth and success we see today is due in part to the solid foundation laid by people like Matt Sorrentino.”

“It was my great honor and privilege to lead a team of dedicated and selfless professionals at HNL, particularly through our community’s fierce battle against COVID-19,” Sorrentino said.

He will continue to serve as a consultant to both LVHN and HNL Lab Medicine. With his retirement, Sorrentino will no longer be an HNL Lab Medicine board member.

Nester said Till’s service on the HNL Board of Directors and the LVHN Board of Trustees provides valuable experience and context to help ensure HNL’s continued growth and success. Till has been part of the LVHN board since 2004 and on the HNL board since 2013. Till will resign both board positions. Kathy O’Brien, a member of the LVHN Board and vice chair of the HNL Board, will replace Till as board chair of HNL.

Till, also an Army veteran, will leave his current job as a partner in ClearLine Development, a real estate development and construction management firm based in the Lehigh Valley, to take the helm at HNL Lab Medicine.

Headquartered in Allentown, HNL Lab Medicine is a leading multiregional, full-service medical laboratory providing testing and related services to physician offices, hospitals, long-term care facilities, employers, and industrial accounts. HNL Lab Medicine has more than 60 Patient Centers located throughout Pennsylvania and New Jersey.